rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, the most common of BRAF mutation (V599E) has not been identified in tumors with K-ras mutations.
|
14513361 |
2003 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V599E) mutation did not coexist with alterations in any of the RAS genes in any of the tumors.
|
12881714 |
2003 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found a high rate of V559E mutations in papillary thyroid carcinomas (47%), one V599E mutation in a well-differentiated gastric endocrine carcinoma (malignant carcinoid), but no activating BRAF mutations in all other endocrine tumors examined.
|
15613458 |
2004 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery.
|
15272920 |
2004 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the V600E mutation in a colorectal MSI-H tumour argues against the presence of a germline mutation in either the MLH1 or MSH2 gene.
|
15342696 |
2004 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Activating point mutation of the BRAF gene resulting in V600E (previously designated as V599E) is a common event in thyroid papillary carcinoma, being found in approx 40% of this tumor.
|
16299399 |
2005 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most prevalent BRAF alteration, V599E, occurred only in tumors with MSI.
|
16015629 |
2005 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, CIMP-high unstable tumors were significantly more likely than their stable counterparts to be KRAS2 wild type, TP53 wild type, poorly differentiated, proximally located, occur at lower stages, and have the BRAF V600E mutation (64.1% vs 17.6%).
|
16143123 |
2005 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A subset of tumors from a total of 55 collected (25 polyps and 30 cancers) from 43 individuals across 11 families underwent pathology review, examination for V599E using allele-specific polymerase chain reaction, and for methylation of the MINT31 CpG island.
|
15765445 |
2005 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We were able to detect the V599E mutation in genomic DNA from paraffin-embedded melanoma samples and could routinely detect this mutation in fine-needle aspirations of melanoma tumors.
|
15737846 |
2005 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We detected one 1796 T-->A BRAF mutation that led to a substitution of valine by glutamic acid at position 599 (V599E) in 40 primary neuroendocrine GEP tumors (3%).
|
15842051 |
2005 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, these studies identify the me</span>chanistic underpinnings by which mutant (V599E)B-RAF promotes melanoma development and show the effectiveness of targeting this protein to inhibit melanoma tumor growth.
|
15781657 |
2005 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Microsatellite-unstable tumors</span> were associated with an excellent 5-year survival whether the V600E mutation was present or absent (76.2% and 75.0%, respectively).
|
16024606 |
2005 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
No statistically significant correlation was found among the presence of B-RAF (V600E) and gender, tumor node metastasis (TNM), multicentricity of the tumor, stage at diagnosis and outcome.
|
16728573 |
2006 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings indicate that adenomas might be less important in the cancer development in the group of families with BRAF-V600E mutations and indirectly support a previous hypothesis that tumors might develop through the hyperplastic polyp-serrated adenoma pathway.
|
17119056 |
2006 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
While univariate analysis showed the BRAF(V600E) mutation was associated with tumour recurrence (21% with mutation vs 7% without mutation; P = 0.037), this association was not shown following multivariate analyses adjusting for the clinicopathological prognostic factors of age, gender, tumour size, extrathyroid extension, multifocality and lymph node metastasis.
|
16918957 |
2006 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of 33 Spitzoid melanomas, only 1 showed the V600E mutation in the B-RAF gene (1 of 33 tumors; 3%).
|
16421887 |
2006 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumours containing wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response).
|
16880785 |
2006 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We have concluded that BRAF(V600E) is a new prognostic factor in PTC that correlates with a high risk of recurrences and less differentiated tumours due to the loss of NIS-mediated (131)I uptake.
|
16601293 |
2006 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To answer this question, the BRAF(V600E) mutational status of individual tumor foci was examined.
|
16983703 |
2006 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutated BRAF (BRAF(V600E)) is a potential immunotherapeutic target for melanoma because of its tumor specificity and expression in the majority of these lesions derived from different patients.
|
16540682 |
2006 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The reference tumor group contained 28 HNPCC with proven germ-line mutations or positive Amsterdam I criteria (median age, 37 years) and loss of MLH1 expression, 14 sporadic MSI-H CRC tumors with loss of MLH1 expression and BRAF V600E mutation (median age, 80.5 years), and 16 sporadic MSS CRC (median age, 76.5 years).
|
17545526 |
2007 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis was analyzed.
|
17972530 |
2007 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
|
16960555 |
2007 |
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was detected in 88 of the tumors examined, with significant differences between groups with and without lymph node (LN) metastases; the mean age of patients with BRAF(V600E) mutation was significantly higher than that of patients without mutations.
|
17685465 |
2007 |